A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 2011-2018

  Marchion, Douglas C ^a   Bicaku, Elona ^a   Xiong, Yin ^a   Zgheib, Nadim Bou ^a   Al Sawah, Entidhar ^a   Stickles, Xiaomang Ba ^a   Judson, Patricia L ^a   Lopez, Alex S ^a   Cubitt, Christopher L ^a   Gonzalez Bosquet, Jesus ^a   Wenham, Robert M ^a   Apte, Sachin M ^a   Berglund, Anders ^a   Lancaster, Johnathan M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

c Met expression; Carboplatin; Combination index; Immunohistochemistry; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; MK 8033; PACLITAXEL; SCATTER FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL GROWTH; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOCYCLOHEPTENES; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84876268884     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2329     Document Type: Article

References (54)

1. Baker VV: Salvage therapy for recurrent epithelial ovarian cancer. Hematol Oncol Clin North Am 17: 977-988, 2003.
2. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9: 1138-1150, 1991.
3. Di Renzo MF, Narsimhan RP, Olivero M, et al: Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6: 1997-2003, 1991. (Pubitemid 21924039)
4. Huntsman D, Resau JH, Klineberg E and Auersperg N: Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 155: 343-348, 1999. (Pubitemid 29370384)
5. Aune G, Lian AM, Tingulstad S, et al: Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol 121: 402-406, 2011.
6. Goode EL, Chenevix-Trench G, Hartmann LC, et al: Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 20: 1638-1648, 2011.
7. Sawada K, Radjabi AR, Shinomiya N, et al: c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67: 1670-1679, 2007. (Pubitemid 46383393)
8. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S and Matsubara O: Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol 24: 1146-1155, 2011.
9. Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S and Matsubara O: Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. Mod Pathol 25: 122-130, 2012.
10. Basha R, Ingersoll SB, Sankpal UT, et al: Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 122: 163-170, 2011.
11. Zillhardt M, Christensen JG and Lengyel E: An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 12: 1-10, 2010.
12. Zillhardt M, Park SM, Romero IL, et al: Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res 17: 4042-4051, 2011.
13. Marchion DC, Cottrill HM, Xiong Y, et al: BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res 17: 6356-6366, 2011.
14. Bicaku E, Xiong Y, Marchion DC, et al: In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer 106: 1967-1975, 2012.
15. Jolliffe IT: Principal Component Analysis. 2nd edition. Springer-Verlag, New York, 2002.
16. Nakamura T, Nawa K and Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122: 1450-1459, 1984. (Pubitemid 14073577)
17. Nakamura T, Teramoto H and Ichihara A: Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA 83: 6489-6493, 1986. (Pubitemid 17174760)
18. Nakamura T, Nawa K, Ichihara A, Kaise N and Nishino T: Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 224: 311-316, 1987.
19. Jeffers M, Rao MS, Rulong S, et al: Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells. Cell Growth Differ 7: 1805-1813, 1996. (Pubitemid 26415177)
20. Montesano R, Matsumoto K, Nakamura T and Orci L: Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67: 901-908, 1991. (Pubitemid 121001504)
21. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J and Birchmeier W: Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384: 173-176, 1996. (Pubitemid 26386473)
22. Bladt F, Riethmacher D, Isenmann S, Aguzzi A and Birchmeier C: Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768-771, 1995.
23. Grant DS, Kleinman HK, Goldberg ID, et al: Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 90: 1937-1941, 1993. (Pubitemid 23069972)
24. Trusolino L and Comoglio PM: Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2: 289-300, 2002. (Pubitemid 37328782)
25. Michalopoulos GK and DeFrances MC: Liver regeneration. Science 276: 60-66, 1997.
26. Sonnenberg E, Meyer D, Weidner KM and Birchmeier C: Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123: 223-235, 1993. (Pubitemid 23284877)
27. Mizuno S and Nakamura T: Hepatocyte growth factor: a regenerative drug for acute hepatitis and liver cirrhosis. Regen Med 2: 161-170, 2007. (Pubitemid 46831077)
28. Trusolino L, Bertotti A and Comoglio PM: MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834-848, 2010.
29. You WK and McDonald DM: The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 41: 833-839, 2008.
30. Sattler M, Reddy MM, Hasina R, Gangadhar T and Salgia R: The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 3: 171-184, 2011.
31. Gumustekin M, Kargi A, Bulut G, et al: HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res 18: 209-218, 2012.
32. El-Attar HA and Sheta MI: Hepatocyte growth factor profile with breast cancer. Indian J Pathol Microbiol 54: 509-513, 2011.
33. Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P and Desiderio MA: Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer 46: 1679-1691, 2010.
34. Kim EJ, Eom SJ, Hong JE, Lee JY, Choi MS and Park JH: Benzyl isothiocyanate inhibits basal and hepatocyte growth factor-stimulated migration of breast cancer cells. Mol Cell Biochem 369: 431-440, 2012.
35. Derman MP, Chen JY, Spokes KC, Songyang Z and Cantley LG: An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C. J Biol Chem 271: 4251-4255, 1996. (Pubitemid 26070529)
36. Li C, Wu JJ, Hynes M, et al: c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141: 2218-2227, 2011.
37. Lee YJ, Kim DH, Lee SH, Kim DW, Nam HS and Cho MK: Expression of the c-Met proteins in malignant skin cancers. Ann Dermatol 23: 33-38, 2011.
38. Syed ZA, Yin W, Hughes K, Gill JN, Shi R and Clifford JL: HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer 11: 180, 2011.
39. Yoshizawa Y, Yamada Y, Kanayama S, et al: Signaling pathway involved in cyclooxygenase-2 up-regulation by hepatocyte growth factor in endometrial cancer cells. Oncol Rep 26: 957-964, 2011.
40. You H, Ding W, Dang H, Jiang Y and Rountree CB: c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 54: 879-889, 2011.
41. Osada S, Kanematsu M, Imai H and Goshima S: Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 55: 544-549, 2008. (Pubitemid 351741499)
42. Eksioglu-Demiralp E, Akdeniz T and Bayik M: Aberrant expression of c-met and HGF/c-met pathway provides survival advantage in B-chronic lymphocytic leukemia. Cytometry B Clin Cytom 80: 1-7, 2011.
43. Que W and Chen J: Knockdown of c-Met inhibits cell proliferation and invasion and increases chemosensitivity to doxorubicin in human multiple myeloma U266 cells in vitro. Mol Med Rep 4: 343-349, 2011.
44. Inno A, Salvatore MD, Cenci T, et al: Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 10: 325-332, 2011.
45. Bu R, Uddin S, Bavi P, et al: HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest 91: 124-137, 2011.
46. Zhou XY, Tomatsu S, Fleming RE, et al: HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA 95: 2492-2497, 1998. (Pubitemid 28145969)
47. Xue X, Taylor M, Anderson E, et al: Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res 72: 2285-2293, 2012.
48. Ba Q, Hao M, Huang H, et al: Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin Cancer Res 17: 7625-7633, 2011.
49. Zhang C and Saunders AJ: An emerging role for Ubiquilin 1 in regulating protein quality control system and in disease pathogenesis. Discov Med 8: 18-22, 2009.
50. Guidi F, Puglia M, Gabbiani C, et al: 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. Mol Biosyst 8: 985-993, 2012.
51. Menashe I, Figueroa JD, Garcia-Closas M, et al: Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background. PLoS One 7: e29396, 2012.
52. Zhang Y and Zhang B: TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6: 1861-1871, 2008.
53. Bolden SW, Hambley JW, Johnston GA and Rogers LJ: Neonatal stress and long-term modulation of GABA receptors in rat brain. Neurosci Lett 111: 258-262, 1990. (Pubitemid 20115634)
54. Burgett AW, Poulsen TB, Wangkanont K, et al: Natural products reveal cancer cell dependence on oxysterol-binding proteins. Nat Chem Biol 7: 639-647, 2011.